This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About doravirine

Updated on 14/10/2019

HIV

Prescribing Information can be accessed here.

Doravirine/3TC/TDF = DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)

A new option in HIV-1

Make doravirine a part of every day

What is doravirine?

DELSTRIGO® (100 mg doravirine/300 mg lamivudine/300 mg tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil) is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.

PIFELTRO® (doravirine) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class.

Prescribing Information can be accessed here.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

 

Doravirine – the next generation NNRTI1,2

See how doravirine can be a part of every day

Efficacy regardless of baseline viral load3,4

Significantly fewer neuropsychiatric adverse events vs. comparator in three pre-specified categories3

Low rates of de novo resistance5,6

Flexible and convenient dosing5,6

 

Doravirine is an NNRTI that has demonstrated efficacy in both treatment-naïve and virologically supressed patients

Having an undetectable viral load supports U=U (undectable =Untransmittable) a global UNAIDS campaign supporting people living with HIV.

De Novo : Newly Acquired; NNRTI = Non-nucleoside Reverse Transcriptase Inhibitor.

View other MSD HIV products...

Related content

 

References

  1. Colombier M-A and Molina J-M. Doravirine: a review. Curr Opin HIV AIDS. 2018;13:308–314.
  2. Feng M, Sachs NA, Xu M, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016;60:2241–2247.
  3. Orkin C, Squires KE, Molina JM, et al.; and DRIVE-AHEAD Study Group. Doravirine/lamivudine/ tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus–1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68(4):535–544.
  4. Molina JM, Squires K, Sax PE, et al.; for the DRIVE-FORWARD Study Group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211– e220. doi:10.1016/S2352-3018(18)30021-3. Epub. 2018 March 25.
  5. DELSTRIGO Summary of Product Characteristics.
  6. PIFELTRO Summary of Product Characteristics.
  7. European Medicines Agency. EPAR summary for the public: nevirapine.
  8. European Medicines Agency. EPAR summary for the public: efavirenz.
  9. European Medicines Agency. EPAR summary for the public: etravirine.
  10. European Medicines Agency. EPAR summary for the public: rilpivirine.

Supporting documentation

PIFELTRO
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

DELSTRIGO
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-DOR-00043 | Date of Preparation: October 2019